Literature DB >> 25982109

Does Age Influence Cardiac Resynchronization Therapy Use and Outcome?

Paul A Heidenreich1, Vivian Tsai2, Haikun Bao3, Jeptha Curtis3, Mary Goldstein4, Lesley Curtis5, Adrian Hernandez5, Pamela Peterson6, Mintu P Turakhia4, Frederick A Masoudi6.   

Abstract

OBJECTIVES: This study sought to describe the use of CRT-D and its association with survival for older patients.
BACKGROUND: Many patients who receive cardiac resynchronization therapy with defibrillator (CRT-D) in practice are older than those included in clinical trials.
METHODS: We identified patients undergoing ICD implantation in the National Cardiovascular Disease Registry (NCDR) ICD registry from 2006 to 2009, who also met clinical trial criteria for CRT, including left ventricular ejection fraction (LVEF) ≤35%, QRS ≥120 ms, and New York Heart Association (NYHA) functional class III or IV. NCDR registry data were linked to the social security death index to determine the primary outcome of time to death from any cause. We identified 70,854 patients from 1,187 facilities who met prior trial criteria for CRT-D. The mean age of the 58,147 patients receiving CRT-D was 69.4 years with 6.4% of patients age 85 or older. CRT use was 80% or higher among candidates in all age groups. Follow-up was available for 42,285 patients age ≥65 years at 12 months.
RESULTS: Receipt of CRT-D was associated with better survival at 1 year (82.1% vs. 77.1%, respectively) and 4 years (54.0% vs. 46.2% , respectively) than in those receiving only an ICD (p < 0.001). The CRT association with improved survival was not different for different age groups (p = 0.86 for interaction).
CONCLUSIONS: More than 80% of older patients undergoing ICD implantation who were candidates for a CRT-D received the combined device. Mortality in older patients undergoing ICD implantation was high but was lower for those receiving CRT-D.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac resynchronization therapy; elderly; heart failure

Mesh:

Year:  2015        PMID: 25982109     DOI: 10.1016/j.jchf.2015.01.012

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN: 2213-1779            Impact factor:   12.035


  6 in total

Review 1.  Heart Failure in Older Adults.

Authors:  Hoda Butrous; Scott L Hummel
Journal:  Can J Cardiol       Date:  2016-05-10       Impact factor: 5.223

2.  Utilization and Efficacy of Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure - A Report From the CHART-2 Study.

Authors:  Hideka Hayashi; Satoshi Yasuda; Makoto Nakano; Yasuhiko Sakata; Kotaro Nochioka; Takashi Shiroto; Yuhi Hasebe; Takashi Noda; Satoshi Miyata; Hiroaki Shimokawa
Journal:  Circ Rep       Date:  2022-05-25

Review 3.  [Chronic heart failure in older patients : Updated national healthcare guidelines on chronic heart failure from a geriatric perspective].

Authors:  Philipp Bahrmann; Roland Hardt
Journal:  Z Gerontol Geriatr       Date:  2018-01-26       Impact factor: 1.281

Review 4.  Sex, Race, and Age Differences of Cardiovascular Outcomes in Cardiac Resynchronization Therapy RCTs: A Systematic Review and Meta-analysis.

Authors:  Bradley McKay; Nicholas W H Tseng; Hassan I Sheikh; Mohammad K Syed; Maureen Pakosh; Jessica E Caterini; Abhinav Sharma; Tracey J F Colella; Kaja M Konieczny; Kim A Connelly; Michelle M Graham; Michael McDonald; Laura Banks; Varinder Kaur Randhawa
Journal:  CJC Open       Date:  2021-09-15

5.  Geographic and Temporal Variation in Cardiac Implanted Electric Devices to Treat Heart Failure.

Authors:  Laura A Hatfield; Daniel B Kramer; Rita Volya; Matthew R Reynolds; Sharon-Lise T Normand
Journal:  J Am Heart Assoc       Date:  2016-07-28       Impact factor: 5.501

Review 6.  Decision-making regarding primary prevention implantable cardioverter-defibrillators among older adults.

Authors:  Paul L Hess; Daniel D Matlock; Sana M Al-Khatib
Journal:  Clin Cardiol       Date:  2019-12-23       Impact factor: 2.882

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.